Efficacy of bone-marrow-derived and placenta-derived multipotent mesenchymal stromal cells for osteoarthritis

Multipotent mesenchymal stromal cells (MMSCs) of different origin are the novel therapeutic agents that can slow down cartilage degeneration, improve reparation and ultimately prevent joint prosthetics. MSCs are capable to direct differentiation into chondrocytes, produce cytokines and growth factors with immunomodulatory and anti-inflammatory effects, stimulate angiogenesis, as well as induce chemotaxis of endogenous progenitors. Bone marrow-derived and placenta-derived MMSCs can be considered the most promising source for cell therapy of joints disorders according to availability, safety, and expected therapeutic efficacy

Study aim: to define the clinical effects of intra-articular transplantation of bone-marrow-derived (BM-MMSCs) and placenta-derived multipotent mesenchymal stromal cells (P-MMSCs) for knee osteoarthritis

Primary Endpoint:

  • Safety of intra-articular injection of stem cells
  • Safety of cell injections will be assessed by reviewing adverse events at 3-time points: (1) up to 3 months post-procedure, (2) up to 6 months post-procedure and (3) at 12 months post-procedure
  • Major adverse events were adjudicated: hospitalization, joint contracture, inflammatory arthritis, tumor formation, death

Dosing regimen: three intra-articular injections of allogeneic P-MMSCs or BM-MMSCs up to 2·107 cells (target dose up to 6·107cells) with 20 mg Hyaluronic Acid at 4-weeks intervals (n=30); control group – Hyaluronic Acid only (n=15)

No HLA matching or immunosuppression required

Efficacy of bone-marrow-derived and placenta-derived multipotent mesenchymal stromal cells for osteoarthritis

Feedback

placenta-consultation